Effects of Ulinastatin on Myocardial Protection and Blood Loss in Patients Undergoing Aortic Valve Replacement

Phase 4

Completed

• Conditions: Abnormal Aortic Valve
• Interventions: Drug: ulinastatin

• Registration Number: NCT00944385
• Lead Sponsor: Yonsei University

Brief Summary

According to TEG (thromboelastography), as maximum amplitude is increased the amount of bleeding and transfusion and Cardiac enzyme is reduced by using ulinastatin.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-06
• Study First Submitted: 2009-07-21
• Study First Submitted QC: 2009-07-22
• Study First Posted: 2009-07-23
• Primary Completion: 2011-04
• Study Completion: 2011-04
• Status Verified: 2011-05
• Last Update Submitted: 2011-05-26
• Last Update Posted: 2011-05-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• 40% below of output of left ventricle
• tricuspid valve failure from moderate to severe
• urgent surgery required
• infectious endocarditis

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
ulinastatin	ulinastatin	Administer with 30,000U /ulinastatin
C group	ulinastatin	administer normal saline

Trial Locations

Locations (1)

Severance Hospital; 🇰🇷 Seoul, Korea, Republic of